Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of GLP-1 receptor agonist use and outcomes in type 2 diabetes mellitus and obesity
NL-OMON61302Phase 4Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- May 2026
- Countries
- 1
01
Overview
Phase 4, open-label trial in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: Changes in cardiometabolic parameters, Infectious disease outcomes and 1 more. Planned start May 2026; status: not yet recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NL-OMON61302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61302.